These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21091110)

  • 21. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
    Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
    Oshima K; Kanda Y; Nakahara F; Shoda E; Suzuki T; Imai Y; Watanabe T; Asai T; Izutsu K; Ogawa S; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2006 Nov; 81(11):875-9. PubMed ID: 16862551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
    Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH
    Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
    Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
    Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
    Muthusamy AS; Vaidya AC; Sinha S; Roy D; Elker DE; Friend PJ
    Am J Transplant; 2008 Oct; 8(10):2126-31. PubMed ID: 18828772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 28. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.
    Silveira FP; Marcos A; Kwak EJ; Husain S; Shapiro R; Thai N; McCurry KR; Abu-Elmagd K; Paterson DL
    J Infect; 2006 Oct; 53(4):241-7. PubMed ID: 16403576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
    Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
    Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab and liver transplantation: a review.
    Dhesi S; Boland B; Colquhoun S
    Curr Opin Organ Transplant; 2009 Jun; 14(3):245-9. PubMed ID: 19417659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
    Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
    Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
    [No Abstract]   [Full Text] [Related]  

  • 35. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P; Hillmen P
    Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
    Karlsson C; Hansson L; Celsing F; Lundin J
    Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab induction in kidney transplantation.
    Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S
    Clin Transpl; 2005; ():343-54. PubMed ID: 17424750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
    Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
    Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.